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Purpose: A method to decrease the risk of rectal toxicity 
during prostate radiotherapy treatments consists of an 
implantation of a rectum spacer (RS). Nevertheless the 
implantation of a RS is expensive and invasive. Therefore a 
decision support system to identify a priori whether a 
specific patient would benefit from a RS would be very 
beneficial. 
We have developed a novel method to predict the CT images 
with a ‘virtual’ RS based on a CT scan without RS. Predictions 
of the gain of dose, and consequently of toxicity reduction 
can be obtained through a validated multifactorial 
nomogram.  
Materials/methods: A patient dataset consisting of 16 
prostate cancer patients with CT imaging prior and after a 
gel RS implantation (SpaceOAR™ System, Augmenix Inc.) was 
used. The median inserted gel volume was 10.5 cc. Gel 
contours of the first 8 patients were used as a training set to 
derive the spatial deformation model of the RS.  
A deformation model of the RS was build, based on 
overlapping volumes of RS’s of different patients with a 
probability of >3 contour corresponded with a volume of 10 
cc. From this model, a deformation field was calculated that 
mimics the expansion of the RS between the prostate and the 
rectum. The CT images of the remaining 8 patients were used 
to validate the virtual RS model, for this the distance 
between the rectum and the prostate was compared for the 
virtual RS and the actual RS. For one patient the dose was 
planned on all 3 CT’s (no, real and virtual spacer) according 
to our clinical practice (70 Gy: 28 x 2.5 Gy). We used a 
validated multifactorial nomogram developed for predicting 
acute and late radio-induced rectal toxicities. 
Results: The average minimum distances between the 
prostate and rectum of all 8 patients in the validation set 
increased with 3.7±2.4 (1SD) mm when the virtual RS was 
applied. For the real RS the average increase in minimum 
distance was 5.4±2.7 mm. The mean distances between the 
prostate and rectum without RS was 15.8±3.2 mm, with the 
virtual RS this was 19.5±3.3 mm comparable to the real RS 
22.0±4.3 mm. 
For one patient the planned dose on all 3 CT’s is shown in the 
table and figure.  
The virtual spacer revealed a large decrease in volume 
receiving more than 65 Gy, which however correlated in no 
significant difference of predicted late toxicity. 
 
 
 
 
 
Conclusions: We have developed a novel method to simulate 
a prostate-rectum spacer that is a useful tool to identify 
patients with a potential dose and outcome benefit of a RS 
implantation. The volume of the virtual RS can be estimated 
through the use of different deformation fields. For the 
presented patient the RS would not give a clinical benefit, so 
this patient should not get a RS. We envision that in the 
future this virtual spacer–based decision support system will 
be used to quantify a priori the potential benefit of such 
approach, more particularly before extremely 
hypofractionated schedules.  
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Purpose: Terbium is a unique element as it provides a 
quadruplet of radionuclides suited for diagnostics and 
therapy in nuclear medicine [1]. As part of the PSI-ISOLDE 
collaboration, we concentrated on the collection and 
purification of 149Tb (α-emitter, T1/2 = 4.1 h – for potential 
therapy) and 152Tb (β+-emitter, T1/2 = 17.5 h – for use in PET 
imaging), for significant imaging and therapy investigations.  
Materials/methods: Mass-separated beams of 149Tb and 152Tb, 
respectively, were implanted at ISOLDE-CERN into Zn-coated 
Au foils. With 1.5 hours of collection and 2 hours decay of co-
implanted activities, up to 200 MBq 149Tb could be 
transported to PSI. Collections of 152Tb lasted 4 to 6 hours 
and up to 2 GBq 152Tb could be shipped to PSI. 
The Tb radionuclides were extracted from the Zn foils by 
dissolving them in HNO3/NH4NO3, loaded on to a macroporous 
strongly acidic cation exchange resin and the Tb 
radionuclides eluted using dilute α-hydroxyisobutyric acid (α-
HIBA).  The product eluent was used directly for the 
radiolabeling process. 
Complementing previous therapy studies with 149Tb-folate 
and 161Tb-folate [2, 3], we focused on the possible side 
effects of such a treatment. Healthy mice, without tumors, 
were injected with increasing activity levels to investigate 
kidney damage after α-therapy with 149Tb-folate and compare 
it with the damage caused by 161Tb-folate-based β-therapy. 
These mice are monitored with regard to potential undesired 
side effects. DOTANOC and DOTA-RGD were also labelled 
with 152Tb, a radionuclide which can potentially be used for 
PET imaging. They were injected into AR42J and U87MG 
tumor-bearing mice, which were imaged using a benchtop 
small animal PET/CT scanner (Genisys8, Sofie Biosciences). 
Results: The 149Tb and 152Tb were effectively separated from 
Ce, Pr, Ba and La, yielding a radionuclidically pure product.  
The product in question was successfully labelled to 
DOTANOC and DOTA-RGD at high specific activity of up to 10 
MBq/nmol and radiochemical purity of >95%. The 149Tb-folate 
dose escalation study was conducted with six mice injected 
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with 5 MBq/mouse and three untreated controls which were 
injected with α-HIBA only. No impairment of animal kidney 
function was observed to date. 
Tumor visualization was readily achieved with both 152Tb-
labeled peptides and, due to the high sensitivity of this 
scanner, it was possible to also image the tumors at late time 
points after injection of the mice. 
Conclusion: The latest run of experiments in the PSI/ISOLDE 
collaboration proved to be the most successful to date, with 
reproducible harvesting of 149Tb and 152Tb and its subsequent 
chemical separation from impurities.  The product was 
successfully labelled to peptides and folate and injected into 
mice for imaging and long-term studies to determine kidney 
damage, in the case of 149Tb.  Following these encouraging 
results, more ambitious studies are planned in future. 
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Over the past years, dual energy CT (DECT) scanners have 
been installed in many radiology departments. Recently, also 
possibilities are under investigation to use this equipment for 
radiotherapy purposes. Several strategies using DECT imaging 
may allow optimization of radiation treatment in a variety of 
fields: e.g. tumour detection and characterization, improved 
dose calculation accuracy, objective normal tissue function 
quantification. DECT allows a robust way of material 
characterization that easily can quantify the electron density 
and effective atomic number. These approaches improve 
radiotherapy dose calculation accuracy. Especially in 
brachytherapy and proton therapy this is necessary due to 
the larger uncertainties in dose calculation compared to high 
energy photon treatments. Other possible applications 
involve advanced metal artifact reduction techniques. The 
use of iodinated contrast material allows an objective 
quantification for quantitative assessment of perfusion of 
tumours and normal tissues. Future perspectives for DECT for 
radiotherapy will be discussed together with the next steps 
for implementation in clinical practice. 
 
221 
Can we replace high quality simulation CT by simple kV-
cone-beam CT images to extract an externally validated 
radiomics signature? 
J.E. van Timmeren1, R.T.H. Leijenaar1, W. van Elmpt 1, P. 
Lambin1 
1Department of Radiation Oncology (MAASTRO), GROW – 
School for Oncology and Developmental Biology, Maastricht 
University Medical Centre (MUMC), Maastricht, the 
Netherlands 
 
Objective: A validated CT-based radiomic signature showed 
to have prognostic information for lung cancer patients1,2. 
The prognostic value of radiomic image features derived from 
cone-beam CT (CBCT) images has not yet been described. 
Furthermore, due to the fact that a CBCT image is acquired 
prior to each fraction it has the potential to monitor 
response to treatment. The goal of this study was to 
investigate the stability and correlation between features of 
the radiomic signature derived from planning CT vs. kV-CBCT 
and between CBCTs of different fractions. 
Material/Methods: A total of 26 stage II-III NSCLC patients 
who received radiation therapy were included in this study. 
The planning CT (CT1), the CBCT prior to the first (CBCT-FX1) 
and second fraction (CBCT-FX2) were used in this study (see 
Figure). CBCT images were registered to CT1 using an 
automatic rigid registration prior to feature extraction. The 
prognostic radiomic signature1 consists of four features: I) 
tumor intensity: ‘Energy’, II) texture: ‘Grey Level 
Nonuniformity, III) wavelet: ‘Grey Level Nonuniformity HLH’ 
and IV) shape: ‘Compactness’. Since a rigid registration was 
used without redelineation, the fourth feature ‘Compactness’ 
was not analyzed since no changes were performed to the 
shape. For the remaining three features, the correlation 
between feature values derived from (1) CT1 and CBCT-FX1 
and (2) CBCT-FX1 and CBCT-FX2 were analyzed. Correlations 
were calculated using an intraclass correlation coefficient 
ICC(2,1).  
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Figure: Images of A) planning CT and B) kV-cone-beam CT  
 
Results: All three features of the radiomic signature I) 
‘Energy’, II) ‘Grey Level Nonuniformity and III) ‘Grey Level 
Nonuniformity HLH’ showed correlation of ICC>0.8 between 
CT1 and CBCT-FX1 (ICC = 0.98, 0.88 and 0.81 respectively) 
and between CBCT-FX1 and CBCT-FX2 (ICC = 0.89, 0.83 and 
0.95 respectively).  
Conclusion: Three features that previously showed to have 
prognostic performance in lung and head & neck cancer 
patients for CT images show a correlation above 0.8 between 
CT1 and CBCT-FX1. The features also show an ICC>0.8 for 
CBCT-FX1 vs. CBCT-FX2, which suggests stability of those 
features using CBCT imaging. These results show the 
potential of CBCT imaging in monitoring treatment and 
acquiring prognostic and predictive information. In the 
future, radiomic features derived from CBCT images will be 
investigated to monitor changes of CBCT features over the 
course of treatment (the so-called “Delta-radiomics” 
approach) and to evaluate its prognostic significance.  
 
Keywords: radiomics, cone-beam computed tomography 
 
References: 
[1]Aerts, H. J. W. L. et al. Decoding tumour phenotype by 
noninvasive imaging using a quantitative radiomics 
approach. Nat. Commun. 5:4006 doi: 10.1038/ncomms5006 
(2014) 
[2]Leijenaar RT, Carvalho S, Hoebers FJ, Aerts HJ, van Elmpt 
WJ, Huang SH, Chan B, Waldron JN, O'sullivan B, Lambin P. 
External validation of a prognostic CT-based radiomic 
signature in oropharyngeal squamous cell carcinoma. Acta 
Oncol. 2015 Oct;54(9):1423-9. 
 
222 
PET-ToF system with highly integrated SiPM readout  
T. Niknejad1, R. Bugalho2, J. Carlos Rasteiro Da Silva1,2, A. Di 
Francesco1, L. Ferramacho2 , C. Leong2, M. Rolo1,4, R. Silva1 , 
M. Silveira2, S. Tavernier2,3, J. Varela1,2 
1 LIP, Lisbon, Portugal 
2 PETsys Electronics, Oeiras, Portugal 
3 Vrije Universiteit Brussel, Belgium 
4 INFN, Turin, Italy 
 
SiPMs allow a dramatic improvement of PET performance. 
The good timing performance of SiPMs will result in better 
Time Of Flight time resolution, and therefore in better 
effective sensitivity.  The small and independent 
photodetector pixels allow using one-to-one coupling 
between a SiPM pixels and a LYSO crystals. This will result in 
significant improvement of the spatial resolution compared 
to PMT base systems. To take advantage of SiPMs in PET 
applications, it is mandatory to have highly integrated 
electronics readout.  
The present work expands the research in SiPM-based PET-
ToF pursued by the authors since several years, in particular 
developing the TOFPET readout ASIC, a 64 channel mixed-
